Shares

20 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2021

Feb 03, 2022

SELL
$3.5 - $5.68 $160,650 - $260,712
-45,900 Closed
0 $0
Q3 2021

Nov 10, 2021

BUY
$3.44 - $6.37 $68,800 - $127,400
20,000 Added 77.22%
45,900 $237,000
Q2 2021

Aug 11, 2021

BUY
$3.86 - $5.78 $73,340 - $109,820
19,000 Added 275.36%
25,900 $110,000
Q1 2021

Apr 26, 2021

BUY
$4.9 - $6.83 $14,700 - $20,490
3,000 Added 76.92%
6,900 $37,000
Q3 2020

Oct 28, 2020

SELL
$7.66 - $10.78 $15,320 - $21,560
-2,000 Reduced 33.9%
3,900 $31,000
Q4 2019

Feb 11, 2020

BUY
$0.72 - $1.43 $4,125 - $8,193
5,730 Added 3370.59%
5,900 $7,000
Q3 2019

Nov 07, 2019

SELL
$1.43 - $3.81 $2,473 - $6,591
-1,730 Reduced 91.05%
170 $0
Q2 2019

Dec 03, 2019

BUY
$3.23 - $5.41 $6,137 - $10,279
1,900 New
1,900 $8,000
Q2 2019

Jul 30, 2019

SELL
$3.23 - $5.41 $6,137 - $10,279
-1,900 Closed
0 $0
Q1 2019

Dec 03, 2019

BUY
$3.63 - $6.06 $6,897 - $11,514
1,900 New
1,900 $8,000
Q1 2019

May 10, 2019

SELL
$3.63 - $6.06 $3,448 - $5,757
-950 Closed
0 $0
Q4 2018

Dec 03, 2019

BUY
$3.76 - $14.16 $3,572 - $13,452
950 New
950 $5,000
Q4 2018

Jan 31, 2019

SELL
$3.76 - $14.16 $3,572 - $13,452
-950 Closed
0 $0
Q3 2018

Dec 03, 2019

BUY
$8.27 - $13.56 $7,856 - $12,882
950 New
950 $13,000
Q3 2018

Nov 14, 2018

SELL
$8.27 - $13.56 $7,856 - $12,882
-950 Closed
0 $0
Q2 2018

Dec 03, 2019

BUY
$10.42 - $13.74 $9,899 - $13,053
950 New
950 $11,000
Q2 2018

Aug 03, 2018

SELL
$10.42 - $13.74 $9,899 - $13,053
-950 Closed
0 $0
Q1 2018

Dec 03, 2019

BUY
$7.1 - $11.56 $6,745 - $10,982
950 New
950 $11,000
Q1 2018

May 09, 2018

SELL
$7.1 - $11.56 $6,745 - $10,982
-950 Closed
0 $0
Q4 2017

Dec 03, 2019

BUY
$6.68 - $8.74 $6,346 - $8,303
950
950 $6,000

Others Institutions Holding ADAP

About Adaptimmune Therapeutics PLC


  • Ticker ADAP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 163,370,000
  • Market Cap $160M
  • Description
  • Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4...
More about ADAP
Track This Portfolio

Track Kbc Group Nv Portfolio

Follow Kbc Group Nv and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Kbc Group Nv, based on Form 13F filings with the SEC.

News

Stay updated on Kbc Group Nv with notifications on news.